Opko Health, Inc. Completes Patient Enrollment In Third Phase 3 Trial Of RAYALDEE™
5/6/2014 11:12:19 AM
MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE: OPK), has completed patient enrollment in the third phase 3 trial of RAYALDEE. This trial is designed to evaluate the product’s long-term safety and efficacy in treating secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
Help employers find you! Check out all the jobs and post your resume.
comments powered by